Physician profile
Sonnel J Patrick
NPI 1184698565
$2,255.67
in general payments reported to CMS, 2019-2025
23 companies · $538 in 2025
The $538 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $70.55 · 2020: $97.54 · 2021: $442 · 2022: $372 · 2023: $607 · 2024: $128 · 2025: $538.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,274.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,273.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $547.79 | 2022-2025 | |
| Glaxosmithkline, LLC. | $286.09 | 2021-2025 | Nucala, Trelegy Ellipta |
| Genentech USA, INC. | $237.28 | 2022-2025 | Xolair |
| Genzyme Corporation | $174.72 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $133.18 | 2019-2025 | Dupixent |
| Abbvie INC. | $131.44 | 2021-2023 | |
| Optinose US, INC. | $119.23 | 2021-2025 | |
| Csl Behring | $77.22 | 2022-2023 | Haegarda |
| Boehringer Ingelheim Pharmaceuticals, INC. | $76.45 | 2020-2022 | |
| Eyevance Pharmaceuticals LLC | $72.86 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $70.11 | 2021-2025 | Tezspire, Airsupra |
| Aimmune Therapeutics, INC. | $62.13 | 2020-2021 | |
| Seqirus USA INC | $46.74 | 2023 | Fluad Quadrivalent, Flucelvax Quadrivalent |
| Covis Pharma Gmbh | $38.26 | 2021 | |
| Amgen INC. | $33.19 | 2023-2024 | Tezspire |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $28.56 | 2019-2022 | |
| Biocryst US Sales Co., LLC | $25.17 | 2023 | Orladeyo |
| Takeda Pharmaceuticals U.S.A., INC. | $19.60 | 2023 | Takhzyro |
| Uswm, LLC | $17.00 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $15.27 | 2020 | |
| Ars Pharmaceuticals Operations, INC. | $15.06 | 2025 | Neffy |
| Pfizer INC. | $14.50 | 2019 | |
| Hikma Pharmaceuticals USA | $13.82 | 2023 | Ryaltris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sonnel Patrick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.